ARNA Arena Pharmaceuticals Inc.

57.9
0  0%
Previous Close 57.9
Open
Price To Book 2.31
Market Cap 2,870,106,821
Shares 49,570,066
Volume 0
Short Ratio
Av. Daily Volume 565,036

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 3 commencement of dosing announced June 17, 2019.
Etrasimod - ELEVATE UC 52
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 2 trial to be initiated 2019.
Etrasimod
Atopic dermatitis (AD)

Latest News

  1. A Company's First Profit Can Mean Big Profits for Investors
  2. Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
  3. Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
  4. Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. (ARNA)
  5. Edited Transcript of ARNA earnings conference call or presentation 8-May-19 8:30pm GMT
  6. Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19
  7. Top Marijuana Stocks on the NASDAQ
  8. Why Is Arena Pharmaceuticals (ARNA) Up 9.1% Since Last Earnings Report?
  9. Does Market Volatility Impact Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) Share Price?
  10. Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors
  11. Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
  12. Cannabis Sector Weekly Update: Sell-Off amid Market Weakness
  13. All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy
  14. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
  15. Arena Pharmaceuticals Inc (ARNA) Q1 2019 Earnings Call Transcript
  16. Did Business Growth Power Arena Pharmaceuticals's (NASDAQ:ARNA) Share Price Gain of 226%?
  17. S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’
  18. Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
  19. Arena Pharmaceutical shares slide after drug maker reports disappointing financial results
  20. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results